LENZ Therapeutics Inc

LENZ Therapeutics is a commercial-stage pharmaceutical company focused on VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for presbyopia, the age-related loss of near vision. The company estimates presbyopia affects about 1.8 billion people globally and 128 million in the United States. VIZZ is a once-daily, preservative-free drop in single-dose vials. It is a predominantly pupil-selective miotic that creates a pinhole effect to restore near vision for up to 10 hours. In the U.S., LENZ sells VIZZ through eye care professional prescriptions, ePharmacy and retail channels, and a telehealth prescribing option launched in July 2026 that includes home delivery. Demand generation relies on nationwide TV and digital consumer marketing. Outside the U.S., LENZ earns license revenue from upfront payments, milestones and sublicensing through partnerships, including Théa, Lotus Pharmaceutical, Arrotex, Lunatus (Middle East distribution) and Everest Medicines (Greater China rights). In Q4 2026 the company is carrying out a reorganization to focus on consumer marketing and sharply reduce operating expenses. CFO Dan Chevallard becomes Interim CEO on December 1, 2026. Updated Oct 28, 2026